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Inhibition of Notch pathway arrests PTEN-deﬁcient
advanced prostate cancer by triggering p27-driven
cellular senescence
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Activation of NOTCH signalling is associated with advanced prostate cancer and treatment
resistance in prostate cancer patients. However, the mechanism that drives NOTCH activa-
tion in prostate cancer remains still elusive. Moreover, preclinical evidence of the therapeutic
efﬁcacy of NOTCH inhibitors in prostate cancer is lacking. Here, we provide evidence that
PTEN loss in prostate tumours upregulates the expression of ADAM17, thereby activating
NOTCH signalling. Using prostate conditional inactivation of both Pten and Notch1 along with
preclinical trials carried out in Pten-null prostate conditional mouse models, we demonstrate
that Pten-deﬁcient prostate tumours are addicted to the NOTCH signalling. Importantly, we
ﬁnd that pharmacological inhibition of g-secretase promotes growth arrest in both Pten-null
and Pten/Trp53-null prostate tumours by triggering cellular senescence. Altogether, our
ﬁndings describe a novel pro-tumorigenic network that links PTEN loss to ADAM17 and
NOTCH signalling, thus providing the rational for the use of g-secretase inhibitors in
advanced prostate cancer patients.
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P
rostate cancer (PCa) is the most commonly diagnosed
tumour type in men and the second leading cause of
cancer-related mortality in the United States of America1,2.
In PCa, enhanced NOTCH activation has been associated with
tumour initiation, progression and treatment resistance3–14.
These ﬁndings, together with the recent demonstration that
docetaxel-resistant PCa cells upregulate NOTCH signalling, have
generated interest for the use of NOTCH inhibitors in PCa
patients11. Activating mutations of NOTCH1 receptor are
frequently found in leukemia and lung cancer15–18. However,
NOTCH mutations in PCa have been infrequently reported,
therefore, how NOTCH signalling is regulated in PCa still
remains elusive. A better understanding of the molecular
mechanism that drives activation of NOTCH signalling in PCa
would be of great relevance for the clinical development of
NOTCH inhibitors for PCa patients.
Activation of NOTCH, initiated either by ligand-receptor
interactions or due to mutations in NOTCH receptor, requires
two consecutive proteolytic cleavages of the NOTCH receptors19.
The ﬁrst cleavage at site S2 is mediated by two members of the
family of a disintegrin and metalloproteases (ADAMs), ADAM10
or ADAM17 (ref. 20), the second at site S3 by the g-secretase
complex21. These events generate the release of NOTCH
intracellular domain (NICD), which translocates into the nucleus
to regulate the transcription of NOTCH target genes22. ADAMs are
membrane-associated metalloproteases that possess a complex
multi-domain structure, with more than half of the members
exhibiting proteolytic potential. Although ADAM10 mediate S2
cleavage in a ligand-dependent manner, ADAM17 cleaves Notch in
the absence of ligand, a process may be important in tumours
overexpressing ADAM17 protein. Interestingly, ADAMs are
upregulated in a number of cancers, including PCa23. In an
attempt to identify the regulators of NOTCH signalling in PCa, we
analysed available gene expression proﬁle data sets24 from different
Pten-deﬁcient prostate conditional mouse models wherein we
found that several NOTCH target genes were strongly upregulated
in these tumours (Supplementary Fig. 1a). PTEN gene alterations
account for nearly 40% of PCa cases wherein it is also responsible
for treatment resistance25–28. Moreover, Pten is a haplo-insufﬁcient
tumour-suppressor gene and variation in Pten protein levels
promote PCa in mice in the absence of Pten genetic alterations29,30.
Previous evidence demonstrates that NOTCH1 activation can
repress PTEN levels initiating tumorigenesis31. However,
whether PTEN loss could activate NOTCH signalling remains
unknown. Here we have put forward the hypothesis that PTEN loss
may trigger NOTCH signalling by regulating the NOTCH
proteolytic cleavage.
Our results show that, in PCa, loss of PTEN enhances the levels
of ADAM17 thereby promoting the activation of NOTCH
signalling. This PTEN/NOTCH axis is sustained by the oncogenic
isoform of the transcription factor (TF) CUX1 (Cut-Like
Homeobox 1) (p110 CUX1), a previously unknown regulator of
ADAM17 transcription. The p110 CUX1 protein is a proteolytic
isoform of the full-length p200 CUX1, cleaved by CathepsinL32.
Recent ﬁndings demonstrate that increased expression of p110
CUX1 functions as a transcriptional activator of genes involved in
tumour cell proliferation and invasiveness33–35. Importantly, we
demonstrate that treatment with a g-secretase inhibitor (GSI) is
highly effective in blocking PCa progression in different Pten-
deﬁcient mouse models of PCa.
Results
Loss of Pten activates Notch signalling in PCa. To study
whether loss of PTEN impacts NOTCH signalling in prostate
tumours, we took advantage of the Pten prostate conditional
mouse model (here after referred to as Ptenpc / )36.
Intracellular proteolytic processing of the NOTCH1 receptor
leads to the generation of NICD1, a marker of NOTCH1
activation37. Immunohistochemical (IHC) and western blot (WB)
analyses for NICD1 showed that Notch signalling is highly
activated in Pten-deﬁcient prostate tumours (Fig. 1a–c). In line
with these observations, Gene Set Enrichment Analysis (GSEA) of
Ptenpc / mouse tumours revealed a Notch signature in
Ptenpc / tumours (Fig. 1d). These data were also validated in
a human PCa data set where PTEN mRNA levels inversely
correlated with Hairy and enhancer of split1 (HES1) levels in PCa
patients at different stages of disease (Supplementary Fig. 1b).
In line with increased levels of NOTCH signature observed
in Ptenpc / tumours, enzymatic activity assay conﬁrmed that
the g-secretase complex was activated to a higher extent in
Ptenpc / tumours as compared with control prostates
(Supplementary Fig. 1c,d).
To evaluate the relevance of Notch1 signalling in Ptenpc /
tumours, we generated prostate conditional knockout of both
Pten and Notch1 in mice (hereafter referred as Ptenpc / ;
Notch1pc / ). We ﬁrst conﬁrmed the prostate-speciﬁc deletion
of both Pten and Notch1 by WB analysis and reverse transcription
PCR (RT-PCR) for Notch target genes (Supplementary Fig. 1e).
Next, we performed histopathological analysis to determine the
effect of combined Pten and Notch1 inactivation in mouse
prostates. Mice were killed at different ages and prostates
were resected from Ptenpcþ /þ , Notch1pc / , Ptenpc / and
Ptenpc / ; Notch1pc / mice. Notably, inactivation of Notch1
in Ptenpc / tumours induced a strong inhibition of tumour
growth compared with age-matched Ptenpc / littermates as
measured by decreased number of glands affected by high-grade
prostatic intraepithelial neoplasia and invasive PCa (Fig. 1e,f and
Supplementary Fig. 1f). Furthermore, Ptenpc / ; Notch1pc /
tumours showed reduced cell proliferation as observed by a
decrease in Ki-67 staining compared with Ptenpc / tumours
(Fig. 1g and Supplementary Fig. 1f). Note that both Ptenpcþ /þ
and Notch1pc / mice did not develop any prostate lesions.
Interestingly, the reduction of cell proliferation in Ptenpc / ;
Notch1pc / tumours was accompanied by a strong increase in
p27 protein levels and upregulation of the senescence-associated
beta-galactosidase staining, two markers of senescence (Fig. 1h,i
and Supplementary Fig. 1g). The enhanced g-secretase activity in
Ptenpc / tumours and their dependence on Notch1 signalling
suggested that Pten-deﬁcient prostate tumours could be highly
responsive to the treatment with GSIs.
PF-03084014 promotes senescence in advanced PCa. Having
demonstrated the relevance of activated Notch1 signalling in
Ptenpc / prostate tumorigenesis, we conducted a preclinical
trial to test the impact of g-secretase inhibition in Ptenpc /
mice. We therefore treated a cohort of Ptenpc / mice with PF-
03084014, a GSI currently in clinical evaluation38,39. Treatment
was started when the prostate tumours were already established at
8 weeks of age (Fig. 2a). At the end of the treatment, mice were
killed and prostate tumours were isolated for analysis. Treatment
with PF-03084014 was well tolerated, as indicated by the absence
of body weight loss (Supplementary Fig. 2a), and mice did not
develop any toxicities with the exception of a spotted loss of hair
pigmentation phenotype, an indicator of the activity of the
compound in vivo (Supplementary Fig. 2b)40,41. Gross anatomy
of different prostate lobes revealed that in Ptenpc / mice
treated with PF-03084014, the tumour size was strongly reduced
when compared with control tumours (Fig. 2b,c). Reduction in
tumour size was associated with an enhanced senescence response
as measured by decreased Ki-67 staining, increased pHP1g
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Figure 1 | Notch1 signalling is activated in Ptenpc / prostate tumours. (a) IHC showing NICD1 and Pten stainings in both Ptenpcþ /þ normal prostate
(8±3%) and Ptenpc / prostatic intraepithelial neoplasia (PIN) lesions resected from 12-week-old mice (25±9%) (n¼ 3). Magniﬁcation  20 and
400. (b) WB showing the protein levels of Pten, total Notch1, NICD1 and Hes1 in both Ptenpcþ /þ prostate and Ptenpc / prostate tumours (n¼ 5).
(c) Quantiﬁcation of b. (d) Gene Set Enrichment Analysis (GSEA) showing activation of Notch1 signalling in Ptenpc / prostate tumours. (e) H&E and
Ki-67 staining of APs derived from 12-week-old Ptenpc / and Ptenpc / ; Notch1pc / tumours (n¼ 5). Magniﬁcation  20 and 40, respectively.
Insets represent H&E and Ki-67 images of Ptenpcþ /þ and Notch1pc / . (f) Histopathological characterization of normal prostates and prostate tumours
in mice of the indicated genotypes (n¼ 16 for each genotype). (g) Quantiﬁcation of Ki-67 staining of APs in mice of indicated genotypes. (h) WB showing
the protein levels of Pten and p27 in Ptenpcþ /þ , Ptenpc / and Ptenpc / ; Notch1pc / prostate tumours. (i) Quantiﬁcation of the percentage of
Senescence-associated beta-galactosidase staining in Ptenpcþ /þ , Ptenpc / and Ptenpc / ; Notch1pc / prostate tumours. Values are expressed as
mean±s.e.m. *Po0.05; **Po0.01; ***Po0.001 by Student’s t-test.
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staining (Fig. 2d–f) and p27 protein levels (Fig. 2g). Interestingly,
upon g-secretase inhibition we found reduced levels of S-phase
kinase-associated protein 2 (Skp2), an inhibitor of p27, that was
previously shown to regulate senescence in Ptenpc / tumours
both by mRNA and protein levels42. Reduced levels of NICD1
and Notch1 target genes, such as Skp2, c-Myc and Hes1,
conﬁrmed that PF-03084014 efﬁciently reached the target in
Ptenpc / tumours (Fig. 2g). GSEA analysis further conﬁrmed
loss of Notch1 signalling in Ptenpc / tumours treated with
PF-03084014 (Fig. 2h). Upregulation of senescence and p27 was
also validated in Pten-null mouse embryonic ﬁbroblasts (MEFs)
treated with PF-03084014 (Supplementary Fig. 2c,d). Notably,
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Figure 2 | PF-03084014 constrains tumorigenesis of Ptenpc / prostate tumours. (a) Scheme of treatment. Mice have been treated twice a day for 4
weeks with either vehicle or PF-03084014 (100mg kg 1). (b) Picture showing the size of anterior (AP), dorso-lateral (DLP) and ventral prostates (VP)
from Ptenpcþ /þ wt prostates and Ptenpc / tumours treated with either vehicle or PF-03084014. (c) Quantiﬁcation of b (n¼ 5). (d) H&E, Ki-67 and
pHP1g staining of APs derived from Ptenpc / tumours treated with either vehicle or PF-03084014. Magniﬁcation 4 and 40. (e,f) Quantiﬁcation of
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treatment of Ptenpc / tumours with PF-03084104 blocked the
expression of Notch1 as conﬁrmed by RT-PCR (Supplementary
Fig. 2e). This data suggest that Notch1 activation induces its own
expression, in line with previously published results43–46. Guided
by the results obtained in Ptenpc / mice, we also assessed the
efﬁcacy of PF-03084014 in more aggressive mouse models of PCa.
Ptenpc / mice from 15 weeks of age and Ptenpc / ;
Trp53pc / develop focal invasive and fully inva-
sive PCa, respectively. In particular, Ptenpc / ; Trp53pc /
tumours are considered highly aggressive and resistant to the
majority of conventional treatments available in the clinic for
PCa36. Treatment was started when the prostate tumours were
invasive (15 weeks of age) and lasted for 5 weeks. Ptenpcþ /þ and
Trp53pc / mice were also included in this trial and used as a
control to assess potential negative effects of PF-03084014 treat-
ment in normal-like prostate tissues. Remarkably, haematoxylin
and eosin and immunoﬂuorescence (IF) staining for Vimentin/
E-Cadherin revealed that, in Ptenpc / ; Trp53pc / mice
treated with PF-03084014, tumour grade and percentage of
invasive glands was signiﬁcantly reduced when compared with
Ptenpc / ; Trp53pc / control mice (Fig. 3a). The reduced
invasiveness was accompanied by decreased proliferation as
measured by Ki-67 staining and reactive tumour stroma (Fig. 3a).
We also observed decreased invasiveness and proliferation in 15-
week-old Ptenpc / tumours upon treatment with PF-03084014,
validating the results obtained with mice at early age
(Supplementary Fig. 3a,b). As observed in Ptenpc / mice,
treatment with PF-03084014 increased p27 levels and decreased
Skp2 protein levels also in Ptenpc / ; Trp53pc / tumours
(Fig. 3b–d). However, treatment with PF-03084014 did not
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change the morphology and proliferation of normal-like prostates
in both Ptenpcþ /þ and Trp53pc / mice (Supplementary
Fig. 3a,b). Finally, treatment of LNCaP and PC3, two PTEN-
deﬁcient human PCa cell lines, with PF-03084014 also showed
signiﬁcant cell growth inhibition upon Notch pathway inhibition
in agreement with our ﬁndings in mice and recent evidence47
(Supplementary Fig. 3c,d). Taken together, these data
demonstrate that NOTCH inhibition is effective in blocking
Pten loss driven tumorigenesis at both early and late stage.
PTEN loss triggers ADAM17 upregulation in PCa. Activation
of the NOTCH1 receptor is a tightly regulated process that relies
on a hierarchically ordered proteolytic cleavage cascade48.
Generation of intracellular NICD1 by the g-secretase complex
follows, and requires, the initial extracellular cleavage of
NOTCH1 by ADAM metalloproteases49. We therefore checked
whether loss of Pten could alter the expression of Adam17, a
metalloprotease that leads to NOTCH activation independently of
the presence of the NOTCH ligand. We found that Adam17 was
upregulated at both the protein and mRNA levels in Ptenpc /
and protein level in Ptenpc / ; Trp53pc / mice (Fig. 4a–c and
Supplementary Fig. 4a). Similarly, ADAM17 was speciﬁcally
upregulated in human PCa cell lines having functional loss of
PTEN in either one (DU-145) or both (LNCaP, PC3) alleles. This
was also associated with increased levels of NICD1 and Hairy/
enhancer-of-split related with YRPW motif protein 1 (HEY1)
(Fig. 4d–f and Supplementary Fig. 4b).
Consistent with our data obtained in Ptenpc / mice, genetic
inactivation of PTEN in DU-145 cells led to an increased
expression of ADAM17 along with NICD1 upregulation
(Supplementary Fig. 4c,d). We next checked the correlation
between the protein levels of PTEN and ADAM17 in two
different tissue microarrays (n¼ 130) of human PCa. Our
analysis revealed that the majority of samples displaying low
levels of PTEN stained positive for ADAM17 (Fig. 4g,i;
P¼ 0.039511). Bioinformatics analysis also showed an inverse
correlation between the gene expression levels of PTEN and
ADAM17 in prostate tumours (Fig. 4h). Low levels of PTEN and
high levels of ADAM17 in tumours correlated with high tumour
grading (Po0.0001) and Gleason score (Po0.0001) (Fig. 4i).
Patients with tumours characterized by low levels of PTEN and
high levels of ADAM17 (PTENlowADAM17high) had also a worse
clinical outcome compared with other patient groups (Supple-
mentary Fig. 4e). Altogether, these data indicate that PTEN loss
drives the upregulation of ADAM17 and the consequent
activation of NOTCH pathway. Importantly, inhibition of
ADAM17 by means of a short hairpin RNA (shRNA) also
decreased NICD1 protein level and reduced the proliferation of
the aggressive human PCa cell line PC3 (Fig. 4j,k).
CUX1 regulates the levels of ADAM17 in prostate tumours.
Our data show that loss of PTEN leads to increased levels of
ADAM17. To assess whether this effect was phosphatidylinositol
30-kinase (PI3K)/AKT dependent, we treated human PCa cell
lines with either normal or functional loss of PTEN with the PI3K
inhibitor, AZD8186. Interestingly, inhibition of PI3K/AKT in
these cells did not affect ADAM17 levels, suggesting that acti-
vation of NOTCH signalling is PI3K/AKT-independent
(Supplementary Fig. 5). We therefore looked for a TF that could
regulate ADAM17 expression in PTEN-deﬁcient tumour cells
independently of the PI3K/AKT pathway. To this end, we
screened in the SABiosciences’ proprietary database (DECODE,
DECipherment Of DNA Elements) for TFs that were predicted to
bind the ADAM17 promoter in both mouse and human. Among
the predicted TFs identiﬁed, CUX1 TF was the only conserved TF
predicted to bind to the promoter of both mouse and human
ADAM17 (Supplementary Table 1). Given that PTEN loss
enhances ADAM17 levels in both mouse and human PCa cells,
we focussed on this TF. Interestingly, evidence exists that p110
CUX1, a cleaved form of full-length CUX1 (p200 CUX1), has a
potential oncogenic function35. Indeed, transgenic mouse model
overexpressing p110 CUX1 develop mammary carcinomas33. We
then checked the expression levels of CUX1 in Ptenpc /
tumours. Surprisingly, WB analysis revealed that p110 CUX1
was overexpressed in Ptenpc / tumours, while p200 CUX1 was
mainly expressed in Ptenpcþ /þ prostates (Fig. 5a,b). The p110
CUX1 isoform is a result of a proteolytic cleavage of the full-
length p200 CUX1 mediated by CathepsinL (Fig. 5a). Consistent
with the high levels of p110 CUX1, we found that CathepsinL was
strongly overexpressed in Ptenpc / tumours (Fig. 5a,b). These
results were further conﬁrmed in Pten / MEFs by both WB
and IF analyses (Fig. 5c,d and Supplementary Fig. 6a). It is
important to note that IF staining also showed an accumulation
of CUX1 in the nucleus of Pten / MEFs (Fig. 5d and
Supplementary Fig. 6b). Importantly, high levels of p110 CUX1
were also observed in all the PCa cells analysed, whereas p200
CUX1 was barely detected (Fig. 5f). Next, we performed
chromatin immunoprecipitation (ChIP) experiment in PC3 to
assess the binding of CUX1 on the promoter of ADAM17. In
agreement with the CUX1-binding site prediction, we found that
CUX1 strongly bound the promoter of ADAM17 (Fig. 5g).
Furthermore, we knocked down CUX1 in PC3 by means of two
different small interfering RNAs (siRNAs). Strikingly,
downregulation of CUX1 in PC3 strongly reduced ADAM17 at
both the gene expression and protein levels (Fig. 5h,i). Similar
results for ChIP and siRNA experiments were obtained in DU-
145 PCa cells (Supplementary Fig. 6c,d). Consistent with the
siRNA experiments, treatment of PC3 with a CathepsinL
inhibitor32, which blocks the conversion of p200 CUX1 in p110
CUX1, decreased the levels of both ADAM17 and NICD1 in PC3
cells (Supplementary Fig. 6e).
p110 CUX1 upregulates ADAM17/NOTCH signalling. Finally,
we investigated whether overexpresion of p110 CUX1 resulted in
activation of NOTCH signalling. Transient overexpression of
p110 CUX1 in the PCa cell line 22Rv1 increased both the
ADAM17 and NICD1 protein levels (Supplementary Fig. 7a,b).
Overexpression of p110 CUX1 in the same cells also increased the
luciferase activity of ADAM17 promoter by nearly 10-fold when
compared with the empty vector (Supplementary Fig. 7c). Pre-
vious ﬁndings showed that overexpression of p110 CUX1 in the
mouse mammary gland led to the formation of invasive breast
cancer33. IHC and WB analyses in the mammary glands of p110
CUX1 transgenic mice showed an enhanced protein expression of
both Adam17 and NICD1 as compared with control mammary
glands (Supplementary Fig. 7d–f). p110 CUX1 overexpression in
the breast carcinoma cell line Hs578T also increased the
expression of ADAM17 and HEY1, a downstream target of
NOTCH (Supplementary Table 2)50, whereas downregulation of
p110 CUX1 in the same cells decreased the NOTCH signalling. In
sum, our ﬁndings demonstrate that p110 CUX1 enhanced the
levels of ADAM17, which in turn leads to NOTCH signalling
activation validating our observation in vivo in different tumour
models.
Discussion
Activated NOTCH signalling has been reported to be associated
with advanced12,13 and metastatic PCa4,8,14. However, the
mechanism behind NOTCH activation in prostate tumours
remained elusive so far. To address this question, we used
Ptenpc / and Ptenpc / ; Trp53pc / mouse models that
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develop high-grade prostatic intraepithelial neoplasia and
invasive prostate tumours, respectively36. In line with human
data, we observed an increased NOTCH signalling in these mouse
models as documented by the increased g-secretase activity and
upregulation of different NOTCH-targeted genes (e.g., Hes1,
Ccnd1). Furthermore, to determine the role of Notch signalling in
Pten loss-driven prostate tumorigenesis, we generated combined
conditional inactivation of Pten and Notch1 in mouse prostatic
epithelia. Strikingly, genetic inactivation of Notch1 in Ptenpc /
mice almost abrogated prostate tumorigenesis by strongly
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reducing cell proliferation. This result demonstrates that prostate
tumours driven by loss of Pten require the activation of Notch1.
Notably, we observed that both genetic and pharmacological
inhibition of NOTCH signalling were associated with inhibition
of proliferation and upregulation of a p27-mediated cellular
senescence response in both Ptenpc / and Ptenpc / ;
Trp53pc / tumours. As previously documented, tumours
affected by the combined loss of Pten and Trp53 are insensitive
to the majority of therapies available in the clinic for PCa, such as
androgen deprivation and docetaxel, and it is therefore surprising
to observe that PF-03084014 is highly effective in this tumour
background51. Activation of p27 in Pten-null tumours was
associated with decreased Skp2 levels. SKP2 is a known
NOTCH target gene and it is a regulator of p27 degradation.
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Treatment with the GSI, PF-03084014, in both Ptenpc / and
Ptenpc / ; Trp53pc / mice strongly decreased the protein
levels of NICD1 and Hes1, thus conﬁrming that the GSI reached
its target. These ﬁndings are in line with a previous study
demonstrating that treatment with a Skp2 inhibitor in a PC3
xenograft mouse model (PC3 cells lack both PTEN and p53)
blocks tumorigenesis by upregulating both p27 and senescence42.
However, SKP2 inhibitors have been associated with several side
effects in humans and their clinical development has been
currently suspended52–55. Therefore, it is interesting to note that
GSIs work just as well as Skp2 inhibitors but with less toxicity.
Our data are also coherent with a recent report demonstrating the
efﬁcacy of PF-03084014 in combination with docetaxel in two
human prostate xenograft mouse models47.
Another major advance of our ﬁndings is the characterization
of the mechanism that links PTEN loss to NOTCH activation in
PCa. As upregulation of NOTCH occurred independently of its
ligand in PTEN-deﬁcient human PCa cell lines, it remained
unclear how aberrant Notch signalling was associated with
development and progression of PCa. Analysis of proteases
involved in activation of Notch signalling has highlighted an
increased S2 processing of Notch receptors mediated by the
ADAM17 metalloprotease. ADAM17 is involved in the ﬁrst
cleavage of the NOTCH receptor that results in the generation of
the NOTCH extracellular domain. This allows the subsequent
cleavage of NOTCH by the g-secretase complex and translocation
of NICD in the nucleus19,22,49. Intriguingly, high levels of
ADAM17 result in S2 cleavage and subsequent activation of
Notch in a ligand-independent manner15,22,49. In our mouse
models and PTEN-deﬁcient human PCa cell lines, we observed an
increase of ADAM17 mRNA levels and an inverse correlation
between PTEN and ADAM17, as assessed by histological staining
in two different tissue microarrays of human PCa. This was also
conﬁrmed by a bioinformatic analysis of additional human PCa
data sets. Furthermore, by knocking down ADAM17 in PC3 PCa
cells, we found decreased NOTCH1 signalling along with
impaired cell proliferation. These data conﬁrmed that NOTCH
activation in PTEN-deﬁcient cells is a consequence of ADAM17
upregulation.
Although the regulation of NOTCH1 activity by ADAM17 has
been extensively investigated19,22,23,49, the regulation of
ADAM17 itself is a lesser-known phenomenon. Various studies
on TFs involved in the upregulation of ADAM17 have shown that
under speciﬁc conditions, such as hypoxia, ADAM17 expression
is upregulated by different TFs56–58. In this study, we found that
CUX1 was the only TF conserved in both mouse and human
predicted to bind to ADAM17. Multiple isoforms of CUX1 have
been identiﬁed out of which two are ubiquitously expressed. One
is the full-length p200 CUX1, known to function as a
transcriptional repressor59, while the other one is a
proteolytically cleaved p110 CUX1 isoform, often regarded as
transcriptional initiator and found to be overexpressed in
multiple cancers35. Although p200 CUX1 is known to
transiently bind to DNA, the p110 isoform can strongly bind to
the promoter region of different genes affecting their
transcription34. In Pten-null prostate tumours and human
cancer cells, we found manifold increase in p110 CUX1 isoform
and an undetectable level of p200 CUX1 when compared with the
control. In our ChIP analysis, we also found several fold increase
in binding of CUX1 to the promoter region of ADAM17 in PCa
cell lines, similar to PIK3IP1, a known target of CUX160.
Knockdown and overexpression of CUX1 in PCa cells also
affected the levels of ADAM17, validating CUX1 as a
transcription activator of ADAM17. This has been also found
in vivo in a different mouse model where overexpression of p110
CUX1 is associated with NOTCH activation. Collectively, our
observations demonstrate that PTEN loss promotes the activation
of NOTCH signalling by upregulating the levels of p110 CUX1
that, in turn, promotes the transcription of ADAM17
(Supplementary Fig. 8). This may happen through an enhanced
proteolytic activity of CathepsinL34, as shown in our study, or
additional mechanisms such as unidentiﬁed proteases or non-
coding RNAs that may lead to either the cleavage or stabilization
of p110 CUX1 mRNA. The results presented in this work
strengthen the potential therapeutic beneﬁts of targeting g-
secretase in PCa and provide a rationale for stratifying patients
who may be more responsive to this treatment owing to loss of
PTEN that mediates activation of NOTCH signalling.
Methods
Mice. PtenloxP/loxP, PtenloxP/loxP; Notch1 loxP/loxP, Notch1 loxP/loxP, Trp53 loxP/loxP
and PtenloxP/loxP; Trp53 loxP/loxP mice (Jackson Laboratory) were crossed with
PB-Cre4 transgenic mice to generate prostate-speciﬁc knockout of Pten and Pten;
Trp53, respectively36. All mice were maintained under speciﬁc pathogen-free
conditions in the animal facilities of the IRB institute, and the experiments were
performed according to the state guidelines and approved by the local ethical
committee. GSI PF-03084014, used for all the preclinical trials in a cohort of
Ptenpc / and Ptenpc / ; Trp53 pc / mice (aged 8 and 15 weeks,
respectively), was synthesized and provided by Pﬁzer. Mice undergoing treatment
were administered control vehicle or therapeutic doses of PF-03084014 by oral
gavage on a monday through friday schedule for a total of 20 days. A dosage of
100mg kg 1 of GSI was administered twice-a-day by oral gavage on monday
through friday schedule. Mice were monitored for any suffering of distress or
weight loss by measuring total body weight of mice biweekly and monitoring the
behavioural changes every day for a total of 4 weeks of treatment. Upon completion
of study, mice were killed by CO2 asphyxiation, and tissues were procured for
histological, mRNA and protein analyses.
Autopsy and histopathology. Animals were autopsied, and all tissues were
examined regardless of their pathological status. Normal and tumour tissue sam-
ples were ﬁxed in 10% neutral-buffered formalin (Sigma) overnight. Tissues were
processed by ethanol dehydration and embedded in parafﬁn according to standard
protocols. Sections (5 mm) were prepared for antibody detection and haematoxylin
and eosin staining. To evaluate evidence of invasion, sections were cut at 20 mm
intervals and haematoxylin and eosin stained. Slides were prepared containing
three to ﬁve of these interval sections.
c-Secretase assay. g-Secretase assays using the recombinant human Notch and
Amyloid precursor protein substrates Notch100-Flag and APP-C100-Flag were
performed as previously reported61–63. Membrane proteins were extracted from
Ptenpcþ /þ - and Ptenpc / -null mice prostate samples in 50mM HEPES (pH
7.0) with 1% CHAPSO. The protein content in the extracts was normalized by BCA
and incubated in 0.2% (wt/vol) CHAPSO, 50mM HEPES (pH 7.0), 150mM NaCl,
5mM MgCl2 and 5mM CaCl2 and incubated at 37 C for 4 h with 1 mm substrate,
0.1% (wt/vol) phosphatidylcholine and 0.025% (wt/vol) phosphatidylethanolamine.
The generated products AICD (Amyloid Intracellular C-terminal Domain)-Flag
and NICD (Notch Intracellular Domain)-Flag were analysed by WB and detected
with Flag-speciﬁc M2 antibody (Sigma-Aldrich).
MEF production and cell culture. Primary MEFs were obtained from individual
embryos of PtenloxP/loxP genotype from a pregnant mouse at 13.5 days postcoitum.
Primary Ptenlox/lox MEFs were infected with retroviruses expressing either
pMSCV-CRE-PURO-IRES-GFP or pMSCV-PURO-IRES-GFP for 48 h and selec-
ted with Puromycin at a concentration of 3 mgml 1. PTEN wild-type (RWPE-1,
22Rv1) human prostate cell lines and heterozygous or homozygous loss of PTEN
function PCa cell lines (DU-145, LNCaP and PC3) were obtained from ATCC and
were cultured according to the manufacturer’s instructions.
Proliferation and senescence assays. Proliferation assay in MEFs was performed
by plating 104 cells per well of 24-well plate in triplicate while that in human PCa
cell lines was performed by plating 1-2 104 cells per well of 24-well plate in
triplicate. Cells were treated with vehicle (dimethyl sulfoxide) control, AZD8186
(PI3K inhibitor, Astrazeneca) at 3 mM and 1 mM and GSI at aforementioned
concentrations. Cell proliferation was monitored on days 0, 2, 4 and 6 whereby
cells were ﬁxed for 15min in a solution of 10% buffered formalin washed with
phosphate-buffered saline (pH7.2) and subsequently stained with 0.01% Crystal
violet solution. Excessive staining was removed by washing with distilled water and
drying the plates overnight. Crystal violet-stained cells were dissolved in 10% acetic
acid solution for 30min on a shaker and the extracted dye was read with a spec-
trophotometer at 590 nm. Cellular senescence in vitro was performed using the
Senescence b-Galactosidase Staining Kit (Cell Signaling) as per the manufacturer’s
instructions.
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siRNA and shRNA transfection. Human ADAM17-directed shRNA was obtained
from Sigma. To prepare lentiviral particles, 293T human embryonic kidneys were
transfected using Jetprime transfection reagents (Polyplus transfection) as per the
manufacturer’s instructions. PC3 cells were infected with the lentivirus from
transfected 293T human embryonic kidneys and were subsequently selected using
puromycin (2mgml 1). shRNA: 50-CCGGCCTATGTCGATGCTGAACAA
ACTCGAGTTTGTTCAGCATCGACATAGGTTTTTG-30 (Clone ID:NM_
003183.3-2002s1c1).
Human CUX1a sequence: 50-AACAGGAGGACACAAGGCAAAGCUG-30and
CUX1b sequence: 50-CAGGGUUUGUUUAAUACACUCCAUU-30 were custom
siRNA synthesized (Dharmacon). siRNA transfection was performed using
Jetprime transfection reagents (Polyplus transfection) as per the manufacturer’s
instructions.
WB and histology. Human tissue microarrays were purchased from Biomax, Inc.
(PR8011A,PR483B). The antibodies used for IHC analysis and WB were anti-
activated Notch1 (Abcam) (IHC), Cleaved Notch1 (Val 1744) (Cell Signaling
Technology; 1:250 dilution), Notch1 (D1E11) (Cell Signaling Technology; 1:1,000)
(WB), PTEN (Cell Signaling Technology; 1:1,000) (WB), PTEN (51–2,400; Invi-
trogen) (IHC), Ki-67 (Clone SP6; Lab Vision) (IHC), HSP90 (Cell Signaling
Technology; 1:1,000), ADAM10 (Abcam; 1:1,000), ADAM17 (Abcam; 1:1,000)
(IHC/WB), CathepsinL (Abcam; 1:1,000) (WB), CUX1 a.a. 1,300 (Millipore,
1:2,500) and CUX1 a.a. 861 (Millipore; 1:1,000) (WB), Skp2 (Santa Cruz; 1:500)
(WB), p27 (Santa Cruz; 1:500) (WB), Hes1 (Santa Cruz; 1:500) (WB), c-Myc (Santa
Cruz; 1:500) (WB), p21 (Santa Cruz; 1:500) (WB) and b-actin (Sigma; 1:5,000)
(WB). IF analysis in prostate tissues was performed by using Vimentin (Abcam,
1:350) and E-cadherin (BD Biosciences 1:400) antibodies.
ChIP assay. Cells were cultured up to a conﬂuence of 90–95% and were crosslinked
with 1% formalin for 10min followed by addition of glycine for 5min at room
temperature. The culture medium was aspirated and the cells were washed twice with
ice-cold phosphate-buffered saline. Nuclear extracts were sonicated using a Misonix
3,000 model sonicator to sheer crosslinked DNA to an average fragment size of
B500 bp. Sonicated chromatin was incubated for 16 h at 4 C with g-bind Plus
sepharose beads (GE Healthcare) conjugated with either anti-CUX1 antibody (Santa
Cruz; 200mg per 0.1ml) or IgG antibody (Millipore) by incubating overnight at 4 C
on a rotor. After incubation, beads were washed thoroughly and then centrifuged.
The chromatin was eluted from the beads, and crosslinks were removed by incu-
bation at 65 C for 5 h. DNA was then puriﬁed using the QIAquick PCR Puriﬁcation
Kit (Qiagen). The ChIP primers for ADAM17 EpiTect ChIP quantitative PCR
(qPCR) Primer Assay For Human ADAM17, NM_003183.4 ( )02Kb (Qiagen) and
PIKChIP1f sequence: 50-GAGGAAGGAAGGTACTGAACC-30 and PIKChIP1r
sequence: 50-CCTGTAACTAAGACATTTATCAGC-30. ChIP qPCR was performed
using KAPA SYBR FAST ABI qPCR Master Mix solution (KAPA Biosystem) on
Step One Real-Time PCR systems (Applied Biosystems). Primers for ADAM17 used
in the ChIP experiments were designed using the SABiosciences’ proprietary data-
base (DECODE, DECipherment Of DNA Elements).
Quantitative real-time PCR. Quantitative real-time PCR was performed on RNA
extracted from cells and the respective tissues samples using Trizol (Invitrogen).
Complementary DNA was prepared with SuperScript III First-Strand Synthesis
SuperMix (Invitrogen). See Supplementary Table 3 for list of primers used for qRT-
PCR. Quantitative real-time PCR was performed using KAPA SYBR FAST ABI
qPCR Master Mix solution (KAPA Biosystem) on Step One Real-Time PCR sys-
tems (Applied Biosystems).
Correlation analysis. Correlation between gene-expression-derived values in the
principle-component analysis PCa data sets was carried out using Pearson’s
correlation test, which estimates a correlation value ‘r’ and a signiﬁcance P value
(r40o1, direct correlation; ro041, inverse correlation). Correlation was also
performed in tissue microarray staining evaluation using the estimated percentage
of positively stained cells. Pearson’s r from correlation analyses was calculated to
assess potential positive (r40) or negative (ro0) linear correlations between the
gene expression levels of PTEN and ADAM17 and between PTEN and HES1 in the
primary tumour biopsies (n¼ 49) comprised in the Grasso human PCA data set
(GSE35988). Two tailed P values o0.05 were considered signiﬁcant.
Gene expression proﬁling. Gene expression proﬁling was carried out using the
MouseRef-8 v2.0 Expression BeadChip (Illumina, San Diego, CA, USA), following
the manufacturer’s protocol. Arrays were read on an Illumina HiScanSQ system.
Data were ﬁrst extracted with the Illumina GenomeStudio software and then
imported in Genomics Suite 6.4 (Partek Incorporated, Saint Louis, MO, USA) and
quantile normalized. Transcripts with differences in expression were identiﬁed by
analysis of variance. Enrichment analysis was performed using GSEA64. Raw data
have been deposited in National Center for Biotechnology Information’s Gene
Expression Omnibus (GEO) and are accessible through GEO accession
(GSE76822). GSEA was performed on entire gene list ranked according to fold
changes observed between Ptenpcþ /þ and Ptenpc / mice and also between
Ptenpc / and Ptenpc / treated with PF-03084014 mice. Functional analysis
was performed on the collapsed gene symbol list using GSEA with the
MSigDB_v4.0 (Molecular Signatures Database)65 C2-C7 gene sets. Gene sets with
false discovery rate o0.25 and Normalized Enriched Score66 41.25 or o 1.25
were considered signiﬁcantly enriched. The VILIMAS_Notch_Targets67 gene set
include 52 genes upregulated in bone marrow progenitors by constitutively active
NOTCH1. Pearson’s correlation was used to study the association among genes in
terms of gene expression. Analyses were performed using the R environment
(R Studio console; RStudio, Boston, MA, USA). A P valueo0.05 was considered
statistical signiﬁcant.
Secrete-pair dual luminescence assay. Cells were co-transfected with ADAM17
promoter reporter clone (HPRM15027, Genecopoeia) along with control vector
(pXJ Vector) and p110 CUX1 (pXJ p110). Media from these transfected cells from
at different speciﬁed time points were collected after changing the media post-
transfection. The secreted luciferase (GLuc and SEAP) was measured and analysed
as per the manufacturer’s guide (SPDA-D010, Genecopoeia).
IF analysis. IF images were acquired on a Leica TCS SP5 confocal microscope,
using a  40/1.25N.A. objective (Leica HCX PL APO lambda blue  40/1.25 oil
UV). Several ﬁelds of views were acquired with tiling scan function in order to get
an area of 1,000 1,000mm2. Image analysis was performed measuring total
ﬂuorescence of TF both in nuclear and cytoplasmic region, with a customized
pipeline in the CellProﬁler software66. Images for tissue samples stained for
Vimentin/E-cadherin were acquired on a Leica TCS SP5 confocal microscope using
 10/1.25 oil.
Statistical analysis. For each independent in vitro experiment, at least three
technical replicates were performed with an exception in WB analysis. In the
in vitro experiments, data groups were assessed for normal distribution and
Student’s t-test was performed for paired comparison. The n values represent the
number of mice used for the study of genetically engineered mouse model analysis
and preclinical trials using PF-03084014.
Data analysis was performed using a two-tailed unpaired Student’s t-test. Values
are expressed as mean±s.e.m. (*Po0.05; **Po0.01; ***Po0.001).
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request. Full scans of WBs are
available in Supplementary Fig. 9.
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